Gilead’s Kite Pharma has agreed to purchase Interius BioTherapeutics for $350 million. This deal will help Kite expand its work in CAR T-cell therapy and gain access to Interius’s cutting-edge in vivo technology. Unlike current CAR T-cell treatments, which require removing and modifying a patient’s cells before reinfusing them, Interius’s approach creates CAR T-cells directly inside the patient’s body. This could make treatment faster and more accessible. The lead product, INT2104, is an investigational gene therapy that could offer long-lasting benefits with a single infusion, eliminating the need for complex cell processing or chemotherapy. Cindy Perettie, Executive Vice President of Kite, said this technology could revolutionize patient care by making treatments simpler and more scalable. Interius’s team and operations will join Kite’s research group in Philadelphia. Phil Johnson, CEO of Interius, noted that this partnership will speed up development, broaden access to treatments, and improve outcomes for patients with serious diseases. INT2104 recently received approval for early-stage clinical trials in Europe for certain blood cancers.